Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Post by RazeKreationson Oct 09, 2022 4:56pm
307 Views
Post# 35015092

Simply Wall Street fair value for MBX $5.74

Simply Wall Street fair value for MBX $5.74This information was extracted from Simply Wall Street Oct/9 2022...................................Share Price vs Fair Value
What is the Fair Price of MBX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MBX (CA$0.51) is trading below our estimate of fair value (CA$5.74)............................
 
Significantly Below Fair Value: MBX is trading below fair value by more than 20%.
Earnings vs Savings Rate: MBX's forecast earnings growth (29.4% per year) is above the savings rate (1.6%).............................
 
Earnings vs Market: MBX's earnings (29.4% per year) are forecast to grow faster than the Canadian market (7.1% per year)...........................
 
High Growth Earnings: MBX's earnings are expected to grow significantly over the next 3 years...................................
 
Revenue vs Market: MBX's revenue (33.7% per year) is forecast to grow faster than the Canadian market (5.8% per year)............................
 
High Growth Revenue: MBX's revenue (33.7% per year) is forecast to grow faster than 20% per year.............................
Debt Level: MBX has more cash than its total debt.
 
Reducing Debt: MBX's debt to equity ratio has reduced from 42.8% to 19.3% over the past 5 years.
 
Debt Coverage: MBX's debt is well covered by operating cash flow (103.2%).
 
Interest Coverage: MBX's interest payments on its debt are well covered by EBIT (3.1x coverage).

<< Previous
Bullboard Posts
Next >>